Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials

Sano, Motoaki; Chen, Shi; Imazeki, Hisae; Ochiai, Hidekazu; Seino, Yutaka

doi:10.1111/jdi.12726

Cited by 39 publications

(24 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant reduction in uric acid levels was seen during treatment with luseogliflozin, consistent with increased urinary excretion of uric acid secondary to luseogliflozin‐induced glycosuria 48 . Taken together, the findings of the current study are consistent with the documented clinical benefits of luseogliflozin in patients with diabetes 49‐54 …”

Section: Discussionsupporting

confidence: 84%

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Kario

Okada

Murata³

et al. 2020

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 84%

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Kario

Okada

Murata³

et al. 2020

J of Clinical Hypertension

View full text Add to dashboard Cite

show abstract

“…Despite a drug-induced decrease in blood pressure, it has been reported that SGLT2 inhibitors do not increase heart rate. For example, among patients with baseline heart rates >80 beats/min (bpm), luseogliflozin was associated with a 7.5-bpm decrease in heart rate compared with a 3.9-bpm decrease in placebo-treated patients ( 48 ). Similarly, dapagliflozin did not increase heart rates compared with placebo ( 49 ).…”

Section: Clinical Efficacymentioning

confidence: 99%

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research

2019

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the most recently approved class of diabetes drugs. Unlike other agents, SGLT2 inhibitors act on the kidney to promote urinary glucose excretion. SGLT2 inhibitors provide multiple benefits, including decreased HbA 1c , body weight, and blood pressure. These drugs have received special attention because they decrease the risk of major adverse cardiovascular events and slow progression of diabetic kidney disease (1-3). Balanced against these impressive benefits, the U.S. Food and Drug Administration-approved prescribing information describes a long list of side effects: genitourinary infections, ketoacidosis, bone fractures, amputations, acute kidney injury, perineal necrotizing fasciitis, and hyperkalemia. This review provides a physiological perspective to understanding the multiple actions of these drugs complemented by a clinical perspective toward balancing benefits and risks.

show abstract

“…SGLT2 inhibitors ameliorate excessive sympathetic nervous activity by suppressing afferent signaling from renal sensory nerves through the improvement of metabolic stress in the kidney. As evidence, SGLT2 inhibitors reduce the heart rate in T2 DM patients with a fast heart rate (17).…”

Section: Kidney Stressmentioning

confidence: 86%

Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?

Sano

2020

Intern. Med.

Self Cite

View full text Add to dashboard Cite

It has become clear that sodium glucose cotransporter (SGLT)-2 inhibitors not only do not increase the incidence of cardiovascular events but they also reduce the duration of hospitalization for heart failure in type 2 diabetes mellitus (T2DM) patients. The administration of SGLT2 inhibitor in T2DM patients with hypertension and a fluid retention tendency lowers the blood pressure and mitigates fluid retention. It also reduces the heart rate in T2DM patients with a fast heart rate. As an explanation for the multifaceted effects of SGLT2 inhibitors on hemodynamics, we hypothesize that these agents act on the inter-organ communication pathway, which modulates the sympathetic nerve activity to the cardiovascular system.

show abstract

Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials

Abstract: We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.

Cited by 39 publications

References 6 publications

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Effects of luseogliflozin on arterial properties in patients with type 2 diabetes mellitus: The multicenter, exploratory LUSCAR study

Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research

Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?

Contact Info

Product

Resources

About